Is Eli Lilly's obesity pill available on the market?

Eli Lilly's oral pill (orforglipron) is still under development and has not yet received broad regulatory approval.

How does this data affect Eli Lilly's stock?

The data may raise concerns about Eli Lilly's competitive position, potentially impacting the stock negatively in the short term.

Eli Lilly's Obesity Pill Trails Wegovy in Prescriptions

Weekly prescription data shows Novo Nordisk's Wegovy holds about 89% of prescriptions, trailing Eli Lilly's obesity pill.

July 15, 2026

2 min read

Source: GuruFocus.com

Key Numbers

wegovy prescription share

89%

According to data from GuruFocus, Novo Nordisk's Wegovy continues to dominate the obesity drug market, capturing about 89% of weekly prescriptions. In contrast, Eli Lilly's (LLY) oral obesity pill lags behind the Danish competitor.

Details

Weekly prescription data shows Wegovy maintained a market share of approximately 89%, indicating sustained strong demand for the injectable obesity treatment. Meanwhile, Eli Lilly's oral pill (orforglipron) has yet to make a significant market breakthrough.

Context

Eli Lilly and Novo Nordisk are fiercely competing in the growing obesity drug market. While Wegovy focuses on weekly injections, Eli Lilly is developing an oral alternative that could be more convenient for patients. However, current prescription data suggests Wegovy remains the preferred choice.

What This Means for Investors

This data may impact investor expectations regarding Eli Lilly's ability to compete in the obesity market. If Eli Lilly's pill fails to gain market share, it could affect the company's revenue growth in this segment.

Frequently Asked Questions

Wegovy captures about 89% of weekly obesity drug prescriptions.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.